Novavax Shares Gain as its Lead Compounds Move Forward, Analysts Review and Target

Novavax Shares Gain as its Lead Compounds Move Forward, Analysts Review and Target


Novavax, Inc. (NASDAQ: NVAX) is a late-stage biotechnology company that drives improved health globally through the discovery and development of innovative vaccines to prevent serious respiratory diseases. In keeping with its stated 2018 objectives, Novavax successfully achieved the crucial milestones during the second and third quarter for its lead ResVax™ and NanoFlu™ programs.


With ResVax, NVAX achieved a critical enrollment goal in the Prepare™ trial, enabling it to reach an agreement with the FDA to initiate a final efficacy analysis in the first quarter of 2019. This analysis will be used to support the future BLA and MAA in the U.S. and Europe, respectively.


Key achievements in ResVax development

Upcoming presentation – The company will share data from its RSV F vaccine program via oral and poster presentations at IDWeek 2018 in the 11th International Respiratory Syncytial Virus Symposium in Asheville, North Carolina, taking place October 31-November 4.

On the NanoFlu front, on Sep 25th, the company announced the initiation of a Phase 2 dose and formulation confirmation clinical trial in older adults of NanoFlu, its nanoparticle seasonal influenza vaccine candidate.


Key achievements in NanoFlu development



Looking ahead to 2019, the company is well poised for rapid growth. Both its RSV and flu programs are conducted in a manner that complies with regulatory agency guidelines in the U.S. and Europe. The company’ products are targeted for worldwide markets (read with NVAX Market Opportunities), its core commercial team is already laying the groundwork before launch with government policymakers, provider, payers, associations, advocates and opinion leaders in advance of regulatory approval.

Our members have booked up to 800% with our recent 2018 NASDAQ and NYSE small cap alerts. We will be initiating coverage on another exciting small cap security mid-week this week (10/14/18). View our recent picks, track record and sign up for our real time mobile/text alerts here

Per, Their average twelve-month price target is $3.6063, suggesting that the stock has a possible upside of 83.06%. The high price target for NVAX is $10.00, and the low-price target for NVAX is $1.35. Considering all this, the company is in an extremely favorable risk-reward position, and value investors should consider exposure in this sector as the backdrop remains favorable.


Below are the excerpts of recent analyst rating on the script:



Description & about the Company: Novavax, Inc. is a late-stage biotechnology company that drives improved health globally through the discovery and development of innovative vaccines to prevent serious respiratory diseases.


ResVax, its RSV vaccine for infants via maternal immunization, is the only vaccine in Phase 3 clinical program and is poised to help prevent the second leading cause of death in children under one year of age worldwide.


Novavax is also advancing the clinical study of its influenza nanoparticle vaccine, which addresses key factors that lead to poor efficacy by currently approved flu vaccines. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce a new class of highly immunogenic particles addressing urgent global health needs.

Pathway to licensure




NVAX Market Opportunities:

  • RSV remains the leading cause of infant hospitalization in the United States, which is exacerbated by the absence of any vaccine to prevent the disease or any widely used treatment other than supportive care once an infant becomes adult.
  • In the U.S. alone, there are approximately 4 million infants born every year, for which 70% of which are infected with RSV during their first year of life.
  • Based on the large untreated market and the severity of RSV disease, management of the company believes that there is at least a $1.5 billion market for ResVax in higher-income countries and apparently, the market opportunity gets much more significant after considering infants in all geographies.
  • The management also expects high uptake of ResVax similar to pediatric vaccine uptake, given the disease burden is high. For pediatric vaccines, compliance, which translates to market penetration, typically reaches in the 90% range.
  • ResVax remains on track to be first-in-class, and the company expects this exclusivity to continue for the foreseeable future.
  • On the flip side, the market for flu vaccines has long been established and growing. It exceeds $3 billion annually. It is generally characterized by several vaccines that historically, were not differentiated from one another. There has been a push in recent years to develop differentiated vaccines.
  • One such vaccine is Fluzone High-Dose. This vaccine has been targeted toward the older-adult population and carries with it a premium price. It has been very successful in capturing the majority of the older-adult market. The Company’ goal is to differentiate its NanoFlu vaccine from Fluzone High-Dose by demonstrating higher and broader-immune responses to a broader range of flu strains.

Anticipated Events:

  • Final efficacy results of the Prepare trial are expected in the first quarter of 2019.
  • Top-line data from the Phase 2 clinical trial of NanoFlu and End of Phase 2 meeting with the FDA are expected in the first quarter of 2019.


Quarterly Financial Results (in, thousands):


Revenue – Novavax revenue in the second quarter of 2018 was $10.8 million, compared to $6.7 million in the same period in 2017. This 60% increase was driven by higher revenue recorded under the Bill & Melinda Gates Foundation (BMGF) grant of $89 million as a result of increased enrollment in the Prepare trial and increased activities of Novavax AB, a wholly owned subsidiary of Novavax.

Profitability – Novavax reported a net loss of $44.5 million, or $0.12 per share, for the second quarter of 2018, compared to a net loss of $44.5 million, or $0.16per share, for the second quarter of 2017. For the six months ended June 30, 2018, the net loss was $90.8 million, or $0.25 per share, compared to a net loss of $88.3 million, or $0.32 per share, for the same period in 2017.

Liquidity and financial flexibility As of June 30, 2018, Novavax had $178.2 million in cash, cash equivalents, marketable securities, and restricted cash, compared to $186.4 million as of December 31, 2017. Net cash used in operating activities for the second quarter of 2018 was $40.0 million, compared to $12.4 million for the same period in 2017. The increase in cash usage was primarily due to the receipt of a $25 million payment under the BMGF grant in the six months ended June 30, 2017, whereas no payment was received in the same period of 2018 (however, the company expect to receive a $15 million payment in the third quarter of 2018).


Key risk factors and potential stock drivers:

  • Successful completion of the upcoming milestones would lead future direction for the company. Any adversities might adversely impact the overall investor sentiments.
  • NVAX has a history of operating losses. Therefore, any time or cost overrun in its ongoing R&D activities and its impact on business & financial profile will remain a key business sensitivity factor.
  • Notwithstanding the expected improvement in the business and financial risk profile of the company, NAVX is still a loss-making entity. Therefore, the company’s ability to achieve successful commercialization will continue to remain a long-term stock sensitivity factor.


Stock Performance

NVAX stock chart


  • On Friday, Oct 12th, 2018, NVAX closed at $1.97, with an average volume of 4.1 million shares exchanging hands. Market capitalization is $753.706 million. The current RSI is 62.05
  • In the past 52 weeks, shares of NVAX have traded as low as $0.96 and as high as $2.75
  • At $1.97, shares of NVAX are trading above its 50-day moving average (MA) at $1.56 and above its 200-day moving average (MA) at $1.71
  • The present support and resistance levels for the stock are at $1.86 & $2.04 respectively.


The Traders News Group

See our recent reports and track record

Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Traders News Source has not been compensated for this report by anyone and the opinions if any are that of the author Vikas Agrawal, CFA. Author’s Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I, wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in the article.
This web site, published by TNS LLC, and is an investment newsletter that is built on the premise of assisting individual investors in learning about investing. Our goal as publishers of financial information is to provide research and analysis of investments to our subscribers. TNS LLC does not give buy or sell recommendations. We do purchase distribution rights from analyst, financial writers and bloggers for a fee that may be licensed to issue price targets and recommendations. Furthermore, we encourage you to speak to a licensed professional prior to making an investment in any type of publicly traded security.
We do sell advertising to other companies including brokerage firms, web sites, publicly traded issuers, investor relations firms, and investment publications, among others. TNS LLC makes no warranty as to the policies of these organizations, and in no way endorses their offers, services, or the content of their advertisements.
When an advertiser is a publicly traded company or a third party acting on behalf of a public company, we fully disclose all compensation in the email advertisement. Such disclosure is included in a disclosure statement in each of the advertisements sent via email.
17B Disclosure
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
PLEASE NOTE WELL: TNS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operator’s owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D.
TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur.
Understand there is no guarantee past performance will be indicative of future results. In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.